1. Energy and cost optimization in the life cycle of nearly zero energy buildings using parametric calculations. (August 2019) Authors: Venus, D; Weiss, T; Moser, C; Hatt, T; Ploß, M; Roßkopf, T Journal: IOP conference series Issue: Volume 323(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ESRA19-0271 Intrathecal administration of hyperbaric prilocaine is a source of systemic O-toluidine. (30th August 2019) Authors: Carini, A; Weiss, T; Koslitz, S; Brüning, T; Guntz, E Journal: Regional anesthesia and pain medicine Issue: Volume 44(2019)Supplement 1 Page Start: A80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OS06.7A METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy. (9th September 2021) Authors: Zhu, L; Blanco-Aparicio, C; Bertero, L; Soffietti, R; Weiss, T; Muñoz, J; Sepúlveda, J; Weller, M; Pastor, J; Valiente, M Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OS08.7.A Lomustine and the immunocytokine L19TNF are a promising treatment combination for recurrent glioblastoma. (5th September 2022) Authors: Look, T; Puca, E; Stucchi, R; Luca, R; Roth, P; Neri, D; Weller, M; Hemmerle, T; Weiss, T Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OS08.8.A Integrin-specific CAR T cells for the treatment of glioblastoma. (5th September 2022) Authors: Villars, D; Hänsch, L; Silginer, M; Weiss, T; Weller, M; Roth, P Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OS10.4.A A macrophage-based drug delivery platform for glioma treatment. (5th September 2022) Authors: Sun, M; Bialasek, M; Rygiel, T; Król, M; Weller, M; Weiss, T Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Outcomes of edoxaban-treated patients with atrial fibrillation and concomitant vascular disease in daily clinical practice: insights from ETNA-AF-Europe. (24th May 2021) Authors: De Vries, TAC; De Groot, JR; Steffel, J; Weiss, T; De Asmundis, C; Kirchhof, P; De Caterina, R Journal: Europace Issue: Volume 23:Supplement 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P01.108 Use of complementary and alternative medicine in glioma patients. (19th September 2018) Authors: Hertler, C; Roelcke, U; Conen, K; Huber, F; Weiss, T; Hofer, S; Heese, O; Westphal, M; Roth, P; Weller, M; Eisele, G Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P10.19.B An immunotoxin targeting CD317 for the treatment of glioblastoma. (5th September 2022) Authors: Gramatzki, D; Weiss, T; Hänsch, L; Silginer, M; Rushing, E J; Roth, P; Gramatzki, M; Peipp, M; Weller, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P10.20.A Mechanisms of synergistic glioma growth suppression by radiotherapy and MET inhibition. (5th September 2022) Authors: Silginer, M; Papa, E; Szabo, E; Vasella, F; Pruschy, M; Stroh, C; Roth, P; Weiss, T; Weller, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗